tiprankstipranks

Cipher Pharmaceuticals Achieves Robust Growth in 2024 with Strategic Acquisition

Story Highlights
Cipher Pharmaceuticals Achieves Robust Growth in 2024 with Strategic Acquisition

Cipher Pharmaceuticals ( (TSE:CPH) ) has issued an update.

Cipher Pharmaceuticals reported significant financial growth in 2024, with total revenue increasing by 58% to $33.4 million, driven by the acquisition of Natroba and strong performance of Epuris. The acquisition of Natroba has provided Cipher with a U.S. commercial footprint, enhancing its growth strategy and cash flow generation, supported by a new credit facility with the National Bank of Canada.

More about Cipher Pharmaceuticals

Cipher Pharmaceuticals is a company in the pharmaceutical industry, focusing on dermatology and infectious disease products. Its primary products include Epuris, a leading product in Canada, and Natroba, which was recently acquired to expand its U.S. market presence.

YTD Price Performance: -19.63%

Average Trading Volume: 16,713

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $203.3M

Find detailed analytics on CPH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App